Amneal Pharmaceuticals Inc (AMRX)
6.505
-0.06
(-0.84%)
USD |
NASDAQ |
Jun 25, 16:00
6.505
0.00 (0.00%)
After-Hours: 20:00
Amneal Pharmaceuticals Research and Development Expense (Annual): 167.78M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 167.78M |
| December 31, 2022 | 200.05M |
| December 31, 2021 | 209.56M |
| December 31, 2020 | 190.58M |
| Date | Value |
|---|---|
| December 31, 2019 | 202.29M |
| December 31, 2018 | 210.45M |
| December 31, 2017 | 191.94M |
| December 31, 2016 | 204.75M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
167.78M
Minimum
2023
209.56M
Maximum
2021
194.05M
Average
200.05M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Fate Therapeutics Inc | 172.60M |
| Ocular Therapeutix Inc | 61.06M |
| Editas Medicine Inc | 177.65M |
| AnaptysBio Inc | 132.28M |
| AEON Biopharma Inc | 34.75M |